<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16409">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006151</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-11645-1</org_study_id>
    <secondary_id>R01DA011645</secondary_id>
    <nct_id>NCT00006151</nct_id>
  </id_info>
  <brief_title>Combining a Smoke Ending Aid With Behavioral Treatment - 1</brief_title>
  <official_title>Combining a Smoke Ending Aid With Behavioral Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Gariti</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to combine a smoke ending aid with behavioral treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prime objective of this Innovative Stage I A/B Behavioral Therapy Development Research
      project is to conduct a pilot study under randomized, double-blind, placebo controlled
      conditions, to provide preliminary estimation of the efficacy of a 6 week Accu Drop nicotine
      fading protocol used in conjunction with cigarette tapering to bring about termination of
      cigarette usage in moderate to heavy smokers (*15 cpd) who are interested in smoking
      cessation. Both the experimental and control groups in this study will receive six weeks of
      the manually driven behavioral treatment by experienced and trained therapists. The
      experimental group (N=30) will also be prescribed active Accu Drops (AD&amp;C) while the control
      condition (N=30) will be prescribed placebo Accu Drops (PD&amp;C) very similar in appearance,
      viscosity, and taste to active Accu Drops. Completion of the study protocol and smoking
      cessation rates at 1 week, 1 month, and 6 months post-treatment will be the prime measures
      of efficacy. The findings of this study will provide sufficient preliminary indication for
      the efficacy of the experimental treatment and its extended investigation in a Phase II
      study or for its nonefficacy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1999</start_date>
  <completion_date type="Actual">February 2002</completion_date>
  <primary_completion_date type="Actual">February 2002</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Abstinence Rate</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The main outcome measures were rates of treatment completion and smoking abstinence. It was hypothesized that the nicotine blocking agent product would lead to higher treatment completion rates, higher abstinence rates, and fewer problems with withdrawal than the placebo group.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Accu Drops (AD&amp;C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group (N=30) will be prescribed active Accu Drops (AD&amp;C) plus behavioral therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control condition (N=30) will be prescribed placebo Accu Drops (PD&amp;C) plus behavioral therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Therapy</intervention_name>
    <description>Weekly behavioral therapy based on Project Match Motivational Therapy clinical manual plus systematic cigarette tapering.</description>
    <arm_group_label>Accu Drops (AD&amp;C)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  21 years of age or older, and no greater than 65 years of age

          -  Medically stable

          -  Smoke at least 15 filtered cigarettes daily

          -  Motivated to quit smoking

        Exclusion Criteria:

          -  Medically unstable

          -  Currently psychiatrically unstable (schizophrenia, unstable psychosis, untreated
             major depression, active substance abuse within the past 6 months)

          -  Pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter W Gariti, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104 6178</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gariti P, Alterman AI, Lynch KG, Kampman K, Whittingham T. Adding a nicotine blocking agent to cigarette tapering. J Subst Abuse Treat. 2004 Jul;27(1):17-25.</citation>
    <PMID>15223089</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 1, 2015</lastchanged_date>
  <firstreceived_date>August 8, 2000</firstreceived_date>
  <firstreceived_results_date>June 24, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Peter Gariti</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>nicotine fading</keyword>
  <keyword>Accu Drop</keyword>
  <keyword>cigarette tapering</keyword>
  <keyword>smoking cessation</keyword>
  <keyword>motivational interviewing</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited to a university based center for the study of addictions in 2002.</recruitment_details>
      <pre_assignment_details>The study used a real world design meaning that participants were randomized on the same day as their study eligibility evaluation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Accu Drops (AD&amp;C)</title>
          <description>The experimental group (N=30) will be prescribed active Accu Drops (AD&amp;C)</description>
        </group>
        <group group_id="P2">
          <title>Placebo (PD&amp;C)</title>
          <description>The control condition (N=30) will be prescribed placebo Accu Drops (PD&amp;C)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Accu Drop Plus Counseling</title>
          <description>Active product and systematic cigarette tapering plus counseling.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Accu Drop Plus Counseling</title>
          <description>Placebo product and systematic cigarette tapering plus counseling</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="47.07" spread="11.4"/>
                <measurement group_id="B2" value="43.50" spread="12"/>
                <measurement group_id="B3" value="45.29" spread="11.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="37"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="23"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Abstinence Rate</title>
        <description>The main outcome measures were rates of treatment completion and smoking abstinence. It was hypothesized that the nicotine blocking agent product would lead to higher treatment completion rates, higher abstinence rates, and fewer problems with withdrawal than the placebo group.</description>
        <time_frame>1 year</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Accu Drop Plus Counseling</title>
            <description>Active product and systematic cigarette tapering plus counseling.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Accu Drop Plus Counseling</title>
            <description>Placebo product and systematic cigarette tapering plus counseling</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Abstinence Rate</title>
            <description>The main outcome measures were rates of treatment completion and smoking abstinence. It was hypothesized that the nicotine blocking agent product would lead to higher treatment completion rates, higher abstinence rates, and fewer problems with withdrawal than the placebo group.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Accu Drops (AD&amp;C)</title>
          <description>The experimental group (N=30) will be prescribed active Accu Drops (AD&amp;C)</description>
        </group>
        <group group_id="E2">
          <title>Placebo (PD&amp;C)</title>
          <description>The control condition (N=30) will be prescribed placebo Accu Drops (PD&amp;C)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Gariti</name_or_title>
      <organization>University of Pennsylvania</organization>
      <email>gar1iti@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
